{"id":57793,"date":"2024-02-27T18:00:17","date_gmt":"2024-02-27T18:00:17","guid":{"rendered":"https:\/\/medsname.com\/ivabrad\/"},"modified":"2026-05-01T10:49:14","modified_gmt":"2026-05-01T10:49:14","slug":"ivabrad","status":"publish","type":"product","link":"https:\/\/medsbase.com\/da\/ivabrad\/","title":{"rendered":"Ivabrad"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Ivabrad?<\/h3>\n<p style=\"margin:0;\"><strong>Ivabrad<\/strong> is 7.5 mg ivabradine tablets from a WHO-GMP certified manufacturer &mdash; a selective inhibitor of the <strong>I<sub>f<\/sub> (&#8220;funny&#8221;) current<\/strong> in the sinoatrial node. Ivabradine was introduced by Servier in 2005 as <strong>Procoralan<\/strong> &mdash; the first drug to selectively slow heart rate without affecting blood pressure, myocardial contractility, or other ion channels. Targets the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels that generate the I<sub>f<\/sub> current responsible for spontaneous SA node depolarisation. selectively blocks I<sub>f<\/sub> in the sinoatrial node, reducing the slope of spontaneous diastolic depolarisation and slowing heart rate. Unlike beta-blockers and non-DHP CCBs, ivabradine has no effect on cardiac contractility, BP, or AV node conduction &mdash; it is a &#8220;pure&#8221; bradycardia agent. Dosing: Start 5 mg twice daily with food; titrate to 7.5 mg twice daily at 2 weeks if resting HR &gt;60 bpm and tolerated. Reduce to 2.5 mg twice daily if HR falls below 50 bpm or symptoms develop. In elderly (&gt;75 yr) start 2.5 mg twice daily. Arrhythmia management is a cardiology-led discipline &mdash; diagnosis, drug selection, and monitoring typically require specialist input. This is not a drug for self-initiated therapy.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Hvad du f\u00e5r med MedsBase:<\/strong> WHO-GMP certificeret producent \u00b7 Diskret emballage \u00b7 Verdensomsp\u00e6ndende forsendelse \u00b7 1.400+ verificerede <a href=\"https:\/\/medsbase.com\/da\/reviews\/\">kundeanmeldelser<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Hver ordre er d\u00e6kket af vores <a href=\"https:\/\/medsbase.com\/da\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.<\/p>\n<h3>Hvorfor bestille fra MedsBase<\/h3>\n<p>Vores generiske medicin kommer fra WHO-GMP certificerede producenter og sendes verdensomsp\u00e6ndende i diskret, neutral emballage \u2014 ingen medicinnavn p\u00e5 pakkens ydre. Kortbetalinger h\u00e5ndteres af en reguleret processor (kontoudtogsbeskrivelser inkluderer en reguleret betalingsprocessor \u2014 aldrig \u201cMedsBase\u201d eller medicinnavn). Crypto og SEPA bankoverf\u00f8rsel accepteres ogs\u00e5. Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy.<\/p>\n<h2 class=\"wp-block-heading\">What Is Ivabrad?<\/h2>\n<p>Ivabrad is 7.5 mg ivabradine tablets from a WHO-GMP certified manufacturer, supplied in 30-180 tablets. Ivabradine was introduced by Servier in 2005 as <strong>Procoralan<\/strong> &mdash; the first drug to selectively slow heart rate without affecting blood pressure, myocardial contractility, or other ion channels. Targets the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels that generate the I<sub>f<\/sub> current responsible for spontaneous SA node depolarisation.<\/p>\n<h2 class=\"wp-block-heading\">How Ivabradine Works<\/h2>\n<p>Ivabradine selectively blocks I<sub>f<\/sub> in the sinoatrial node, reducing the slope of spontaneous diastolic depolarisation and slowing heart rate. Unlike beta-blockers and non-DHP CCBs, ivabradine has no effect on cardiac contractility, BP, or AV node conduction &mdash; it is a &#8220;pure&#8221; bradycardia agent.<\/p>\n<h2 class=\"wp-block-heading\">Godkendte anvendelser<\/h2>\n<ul>\n<li><strong>Chronic symptomatic heart failure with reduced ejection fraction (HF-REF)<\/strong> &mdash; in patients with EF &le;35%, sinus rhythm, and heart rate &gt;70 bpm despite maximum-tolerated beta-blocker (or beta-blocker intolerance). <strong>SHIFT trial evidence.<\/strong><\/li>\n<li><strong>Kronisk stabil angina<\/strong> &mdash; add-on to beta-blocker or alone where beta-blockers are contraindicated. <strong>BEAUTIFUL and SIGNIFY trials.<\/strong><\/li>\n<li>Inappropriate sinus tachycardia (off-label)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Dosering og monitorering<\/h2>\n<p><strong>Dosering:<\/strong> Start 5 mg twice daily with food; titrate to 7.5 mg twice daily at 2 weeks if resting HR &gt;60 bpm and tolerated. Reduce to 2.5 mg twice daily if HR falls below 50 bpm or symptoms develop. In elderly (&gt;75 yr) start 2.5 mg twice daily.<\/p>\n<p><strong>Overv\u00e5gning:<\/strong><\/p>\n<ul>\n<li><strong>Baseline:<\/strong> 12-lead ECG (confirm sinus rhythm, assess HR and QT), BP, U&amp;E.<\/li>\n<li><strong>2-4 weeks:<\/strong> HR review; titrate up or down.<\/li>\n<li><strong>L\u00f8bende:<\/strong> periodic HR and ECG; target resting HR 50-60 bpm in HF-REF.<\/li>\n<li><strong>Stop ved:<\/strong> symptomatic bradycardia (HR &lt;50 with symptoms), new AF (ivabradine efficacy is sinus-rhythm dependent), visual phenomena severe enough to affect driving\/work.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Bivirkninger<\/h2>\n<ul>\n<li><strong>Luminous phenomena (phosphenes)<\/strong> &mdash; transient enhanced brightness in peripheral vision (15%); usually improves spontaneously. Mechanism: ivabradine also weakly blocks I<sub>h<\/sub> current in retinal photoreceptors.<\/li>\n<li><strong>Bradykardi<\/strong> &mdash; dose-limiting (5-10%)<\/li>\n<li><strong>Atrieflimren<\/strong> &mdash; modest excess vs placebo in trials; the drug is not effective once sinus rhythm is lost<\/li>\n<li><strong>Hovedpine, svimmelhed<\/strong><\/li>\n<li><strong>First-degree AV block, ventricular extrasystoles<\/strong><\/li>\n<li><strong>Udsl\u00e6t<\/strong><\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Kontraindikationer<\/h2>\n<ul>\n<li>Resting HR &lt;70 bpm before starting<\/li>\n<li>Cardiogenic shock, acute MI<\/li>\n<li>Sv\u00e6r hypotension<\/li>\n<li>Sick sinus syndrome, sinoatrial block, third-degree AV block without pacemaker<\/li>\n<li>Unstable or acute heart failure<\/li>\n<li>Atrial fibrillation (not effective; may worsen rate control)<\/li>\n<li>Pacemaker-dependent<\/li>\n<li>Sv\u00e6r leversvigt<\/li>\n<li>Strong CYP3A4 inhibitor co-therapy<\/li>\n<li>Graviditet og amning<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">L\u00e6gemiddelinteraktioner<\/h2>\n<ul>\n<li><strong>St\u00e6rke CYP3A4-h\u00e6mmere \u2014 KRITISK.<\/strong> Contraindicated: clarithromycin, itraconazole, ketoconazole, ritonavir, nefazodone, nelfinavir. Caution with moderate inhibitors (diltiazem, verapamil \u2014 note these also add bradycardia independently).<\/li>\n<li><strong>Diltiazem, verapamil<\/strong> &mdash; avoid (additive bradycardia + CYP3A4 inhibition).<\/li>\n<li><strong>QT-forl\u00e6ngende l\u00e6gemidler<\/strong> &mdash; caution; ivabradine has minimal intrinsic QT effect but combined risk rises.<\/li>\n<li><strong>Grapefrugtjuice<\/strong> &mdash; raises ivabradine levels.<\/li>\n<li><strong>Betablokkere<\/strong> &mdash; combination is standard in HF-REF where beta-blocker alone is inadequate; watch for additive bradycardia.<\/li>\n<\/ul>\n<h2 id=\"faqs\">Ofte stillede sp\u00f8rgsm\u00e5l<\/h2>\n<h3 class=\"wp-block-heading\">What are the visual phosphenes?<\/h3>\n<p>About 15% of patients experience transient enhanced brightness in peripheral vision &mdash; particularly when looking from dim to bright light. They are benign (ivabradine weakly blocks a similar current in retinal photoreceptors) and usually adapt over weeks. Severe phenomena that affect driving or work are indication to stop.<\/p>\n<h3 class=\"wp-block-heading\">Can I take ivabradine if I have atrial fibrillation?<\/h3>\n<p>No &mdash; ivabradine only slows the sinoatrial node, so it has no effect on AF and may even make rate control worse. In AF use beta-blockers, non-DHP CCBs, or digoxin instead.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Ivabrad in pregnancy?<\/h3>\n<p>Generally no. Ivabradine has animal teratogenicity data; pregnancy is contraindicated in the licensed indications.<\/p>\n<h3 class=\"wp-block-heading\">Where can I buy Ivabrad online?<\/h3>\n<p>You can buy Ivabrad (ivabradine 7.5 mg, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.<\/p>\n<h2 class=\"wp-block-heading\">Relaterede kardiovaskul\u00e6re l\u00e6gemidler<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/da\/abana\/\">Abana \u2014 Ayurvedisk hjerteformulering<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/aldactone\/\">Aldactone \u2014 Spironolacton<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/cardace\/\">Cardace \u2014 Ramipril (ACE-h\u00e6mmer)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/ecosprin\/\">Ecosprin \u2014 Aspirin 75\/150 mg (antiplatelet)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/lonitab\/\">Lonitab \u2014 Minoxidil 5 mg (oral vasodilator)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/vymada\/\">Vymada \u2014 Sacubitril\/Valsartan ARNI<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/high-blood-pressure-medication\/\"><strong>Se alle h\u00f8jtryksmedicin<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 Medicinsk ansvarsfraskrivelse.<\/strong> Denne side er kun til informationsform\u00e5l og erstatter ikke l\u00e6gefaglig r\u00e5dgivning fra en kvalificeret sundhedsfaglig person. Hypertension, hjerteinsufficiens og arytmier kr\u00e6ver diagnose, overv\u00e5gning og individuel dosering af en l\u00e6ge \u2014 brug altid beta-blokkere under l\u00e6gelig vejledning.<\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Relaterede alternativer<\/h3>\n<p>Andre produkter inden for <strong>Kroniske tilstande<\/strong> som kunder ogs\u00e5 ser:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/da\/prilox-cream\/\">Prilox Cream<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/rozucor\/\">Rozucor<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/lasix\/\">Lasix<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/meftal\/\">Meftal<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/carvego\/\">Carvego<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Ivabrad is ivabradine 7.5 mg tablets \u2014 the first selective I-f current inhibitor, acting at the sinoatrial node to slow heart rate without affecting blood pressure, contractility, or AV conduction. Originally Servier Procoralan (2005). SHIFT trial validated in HF-REF with HR >70 despite beta-blocker; BEAUTIFUL\/SIGNIFY extended evidence to chronic stable angina. Only effective in sinus rhythm \u2014 not for atrial fibrillation. Contraindicated with strong CYP3A4 inhibitors.<\/p>","protected":false},"featured_media":57794,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3260,3356],"product_tag":[4359,4360],"class_list":{"0":"post-57793","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-heart-blood-pressure","9":"product_cat-high-blood-pressure-medication","10":"product_tag-ivabrad","11":"product_tag-ivabradine","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product\/57793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/comments?post=57793"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/media\/57794"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/media?parent=57793"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_brand?post=57793"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_cat?post=57793"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_tag?post=57793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}